Kevin A. David

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era

Andrew M. Evens, Kevin A. David, Irene Helenowski et al. · Journal of Clinical Oncology · 2010 · 317 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Low Incidence of Perioperative Chemotherapy for Stage III Bladder Cancer 1998 to 2003: A Report From the National Cancer Data Base

Kevin A. David, Matthew I. Milowsky, Jamie Ritchey et al. · The Journal of Urology · 2007 · 245 citations

Medicine, Oncology, Urology +11

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder et al. · The Lancet Haematology · 2020 · 142 citations · Full text

Pharmacy, Immunology, Oncology +17

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh et al. · Blood · 2021 · 124 citations · Full text

Medicine, Oncology, Pathology +12

PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

Savita Bhalla, Sriram Balasubramanian, Kevin A. David et al. · Clinical Cancer Research · 2009 · 98 citations · Full text

Life Sciences, Oncology, Pharmacology +17